Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Motegrity ingredients?
How long have hydroxyzine pamoate been on the market?
Drugpatentwatch crizotinib?
Patent expiry trametinib?
How many years does kadcyla's market exclusivity last?

What specific receptor does nivolumab bind to boost the immune system?

See the DrugPatentWatch profile for nivolumab

What receptor does nivolumab bind to?

Nivolumab binds to the PD-1 (programmed death-1) receptor on T cells. By blocking the PD-1 pathway, it helps lift the “brakes” on T-cell activity, allowing the immune system to attack tumors more effectively. [1]

How does blocking PD-1 boost immune activity?

PD-1 normally dampens T-cell responses after it engages its ligands (PD-L1/PD-L2). When nivolumab blocks PD-1, the interaction is disrupted, so T cells can remain more active and sustain anti-tumor immune responses. [1]

Is nivolumab the same as drugs that bind PD-L1?

No. Nivolumab binds PD-1 on T cells, while separate immunotherapies target PD-L1 on tumor cells and/or other cells in the tumor environment. Both approaches affect the PD-1 signaling pathway, but the binding target differs. [1]

Sources

  1. https://www.drugbank.com/drugs/DB01247


Other Questions About Nivolumab :

nivolumab patent expiry How are nivolumab's side effects managed during treatment? Nivolumab originator? How does insurance coverage affect nivolumab affordability? What is the average number of nivolumab doses per treatment? How does nivolumab's binding change with different gene mutations? Is nivolumab given to patients on a weekly or biweekly basis?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
78
Visibility
77
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
mentioned only
Brand Perception
Best Known For

Nivolumab binds to the PD-1 receptor on T cells.

Core Claims
  • Nivolumab binds to the PD-1 receptor on T cells.
  • Blocking the PD-1 pathway helps lift the “brakes” on T-cell activity to attack tumors more effectively.
  • PD-1 normally dampens T-cell responses after engaging PD-L1/PD-L2.
  • When nivolumab blocks PD-1, T cells can remain more active and sustain anti-tumor immune responses.
  • Nivolumab is not the same as drugs that bind PD-L1.
Differentiators
  • Binding target is PD-1 on T cells (not PD-L1 on tumor/other cells).
  • Disrupts PD-1 interaction with PD-L1/PD-L2 to keep T cells active.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugBank 5%
50 # No